Redmile Group’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14.4M | Hold |
|
|||||
|
2025
Q1 | $10.2M | Hold |
|
|||||
|
2024
Q4 | $21.2M | Sell |
|
|||||
|
2024
Q3 | $46.1M | Hold |
|
|||||
|
2024
Q2 | $43.2M | Hold |
|
|||||
|
2024
Q1 | $96.7M | Hold |
|
|||||
|
2023
Q4 | $49.3M | Buy |
|
|||||
|
2023
Q3 | $27.8M | Hold |
|
|||||
|
2023
Q2 | $62.5M | Buy |
|
|||||
|
2023
Q1 | $73.9M | Hold |
|
|||||
|
2022
Q4 | $131M | Hold |
|
|||||
|
2022
Q3 | $290M | Hold |
|
|||||
|
2022
Q2 | $321M | Hold |
|
|||||
|
2022
Q1 | $502M | Hold |
|
|||||
|
2021
Q4 | $758M | Hold |
|
|||||
|
2021
Q3 | $768M | Hold |
|
|||||
|
2021
Q2 | $1.12B | Hold |
|
|||||
|
2021
Q1 | $1.07B | Buy |
|
|||||
|
2020
Q4 | $1.15B | Hold |
|
|||||
|
2020
Q3 | $505M | Hold |
|
|||||
|
2020
Q2 | $433M | Buy |
|
|||||
|
2020
Q1 | $249M | Hold |
|
|||||
|
2019
Q4 | $220M | Hold |
|
|||||
|
2019
Q3 | $174M | Buy |
|
|||||
|
2019
Q2 | $210M | Hold |
|
|||||
|
2019
Q1 | $182M | Hold |
|
|||||
|
2018
Q4 | $133M | Hold |
|
|||||
|
2018
Q3 | $169M | Buy |
|
|||||
|
2018
Q2 | $75.5M | Hold |
|
|||||
|
2018
Q1 | $65M | Buy |
|
|||||
|
2017
Q4 | $33.4M | Buy |
|
|||||
|
2017
Q3 | $5.62M | Hold |
|
|||||
|
2017
Q2 | $4.6M | Hold |
|
|||||
|
2017
Q1 | $6.46M | Hold |
|
|||||
|
2016
Q4 | $3.56M | Sell |
|
|||||
|
2016
Q3 | $4.45M | Sell |
|
|||||
|
2016
Q2 | $2.55M | Buy |
|
|||||
|
2016
Q1 | $2.68M | Sell |
|
|||||
|
2015
Q4 | $7.99M | Buy |
|
|||||
|
2015
Q3 | $11.1M | Buy |
|
|||||
|
2015
Q2 | $13M | Buy |
|